Scott Moonly
General Partner @ Alta Life Sciences
Orange, United States
Scott Moonly is a seed investor at Alta Life Sciences in Orange focused on Medical Device and Mobile. Scott Moonly - General Partner @ Alta Life Sciences
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Scott Moonly invests in
Stages Scott Moonly invests in
Countries Scott Moonly invests in
Investment Focus
Industry
- Medical Device 2 (67%)
- Mobile 1 (33%)
- Health Care 1 (33%)
- Neuroscience 1 (33%)
- Therapeutics 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Series E 1 (33%)
Country
- Spain 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $104M / Series E / May 27, 2021 | |
|
|
INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $19.8M / Series A / Mar 26, 2021 | |
|
|
INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $1.3M / Seed / Jun 11, 2020 |
Co-Investors
About Alta Life Sciences
Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.
Alta Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Guy P. Nohra
Managing General Partner
|
|||
|
Scott Moonly
General Partner
|
|||
|
José Antonio Mesa
Partner
|
|||
|
Miguel Valls
General Partner
|
|||
|
Montserrat Vendrell
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Scott Moonly invest in?
Scott Moonly invests primarily in Medical Device, Mobile and Health Care startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Scott Moonly last invest?
The most recent investment recorded for Scott Moonly closed in May 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!